Bolt Biotherapeutics, INC 10-Q quarterly reports

Bolt Biotherapeutics, Inc. reported a net loss of $7.7 million for Q2 2026 and faces substantial doubt about its ability to continue as a going concern.

Bolt Biotherapeutics reported a net loss of $7.2 million for Q1 2026, a decrease from the prior year, but highlighted substantial doubt about its ability to continue as a going concern.

Bolt Biotherapeutics reported a net loss of $7.1 million for Q3 2025 and announced a new restructuring plan including a 50% workforce reduction to preserve cash.

Bolt Biotherapeutics reported a reduced net loss in Q2 2025, driven by lower operating expenses following a strategic restructuring and pipeline prioritization, despite ongoing going concern doubts.

Bolt Biotherapeutics announces its Q1 2025 financial results, highlighting a net loss of $11.0 million and expressing substantial doubt about its ability to continue as a going concern.

Bolt Biotherapeutics announced its Q3 2024 financial results, highlighting a strategic shift towards key programs and a workforce reduction.

Bolt Biotherapeutics announced its second quarter 2024 financial results, highlighting a strategic pipeline prioritization and restructuring plan.

Bolt Biotherapeutics will discontinue development of trastuzumab imbotolimod and reduce its workforce by approximately 50% to focus on next-generation ISAC platform and reduce operating expenses.